38 active trials 22 recruiting 10 Phase 3 12 disease areas 16 changes in 30 days
13 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 11 with minor changes only.
Primary and study completion pushed from Mar 31, 2027 to Sep 30, 2028
Astellas Pharma Global Development, Inc.Phase 3 NCT06901531 Registry history of NCT06901531 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Astellas Pharma Global Development, Inc.Phase 1 NCT07773129 Registry history of NCT07773129 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Astellas Pharma Global Development, Inc.Phase 3 NCT05621616 Registry history of NCT05621616 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 65 → 58 locations
Astellas Pharma Global Development, Inc.Not specified NCT06779773 Registry history of NCT06779773 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 17 → 22 locations
And 1 more change in the last 30 days
Astellas Pharma Global Development, Inc.Phase 3 NCT07566052 Registry history of NCT07566052 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 13 → 22 locations
Astellas Pharma Global Development, Inc.Phase 1 NCT05997615 Registry history of NCT05997615 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 14 → 19 locations
Astellas Pharma Global Development, Inc.Phase 3 NCT07566156 Registry history of NCT07566156 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 47 → 54 locations
Astellas Pharma Global Development, Inc.Phase 3 NCT05970172 Registry history of NCT05970172 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 62 → 79 locations
Astellas Pharma Global Development, Inc.Phase 3 NCT07409272 Registry history of NCT07409272 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 33 → 48 locations
Astellas Pharma Global Development, Inc.Phase 2 NCT07475806 Registry history of NCT07475806 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 17 → 21 locations
Astellas Pharma Global Development, Inc.Phase 1/2 NCT07488676 Registry history of NCT07488676 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 30, 2026 to Mar 31, 2027
Astellas Pharma Global Development, Inc.Phase 3 NCT03653507 Registry history of NCT03653507 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 30, 2026 to Mar 31, 2027
Astellas Pharma Global Development, Inc.Phase 2 NCT04225117 Registry history of NCT04225117 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-09-21 | NCT07829757 A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With… | Phase 4 | Not Yet Recruiting |
| Phase 1 | 12 | |
| Phase 1/2 | 6 | |
| Phase 2 | 6 | |
| Phase 3 | 10 | |
| Phase 4 | 2 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06862219 | A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer | Metastatic Urothelial Carcinoma | Recruiting | 2026-08-21 |
| NCT07829757 | A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With… | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Not Yet Recruiting | 2026-09-21 |
| Phase 3 | ||||
| NCT07566052 | A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell… | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2026-10-08 |
| NCT07566156 | Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy… | Urothelial Cancer | Recruiting | 2026-09-30 |
| NCT06901531 | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With… | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Recruiting | 2026-09-24 |
| NCT05970172 | A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney… | Chronic Kidney Disease | Recruiting | 2026-09-22 |
| NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either… | Pancreatic Cancer | Recruiting | 2026-09-22 |
| NCT07673887 | A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric… | Gastric Adenocarcinoma | Recruiting | 2026-09-11 |
| NCT03653507 | A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as… | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Active, Not Recruiting | 2026-09-28 |
| NCT06440967 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer… | Hot Flashes | Active, Not Recruiting | 2026-09-22 |
| NCT04223856 | Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced… | Urothelial Cancer | Active, Not Recruiting | 2026-05-29 |
| NCT03504397 | A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy… | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Active, Not Recruiting | 2026-05-04 |
| Phase 2 | ||||
| NCT07475806 | A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With… | Muscle-invasive Bladder Cancer | Recruiting | 2026-09-24 |
| NCT07005154 | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | Prostate Cancer | Recruiting | 2026-09-03 |
| NCT04225117 | A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic… | Locally Advanced or Metastatic Malignant Solid Tumors | Active, Not Recruiting | 2026-09-23 |
| NCT02960022 | A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide… | Prostate Cancer | Active, Not Recruiting | 2026-09-11 |
| NCT03505320 | A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer | Pharmacokinetics of Zolbetuximab | Active, Not Recruiting | 2026-08-31 |
| NCT03816163 | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | Pancreatic Cancer | Active, Not Recruiting | 2026-07-14 |
| Phase 1/2 | ||||
| NCT07488676 | A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other… | Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | Recruiting | 2026-09-22 |
| NCT07730021 | A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid… | Locally Advanced or Metastatic Solid Tumors | Recruiting | 2026-09-18 |
| NCT07770685 | A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related… | Glaucoma | Recruiting | 2026-09-11 |
| NCT07287995 | A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid… | Locally Advanced or Metastatic Malignant Solid Tumors | Recruiting | 2026-09-02 |
| NCT05520567 | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People… | Acute Myeloid Leukemia (AML) | Active, Not Recruiting | 2026-09-11 |
| NCT06792435 | XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | Pancreatic Adenocarcinoma Metastatic | Active, Not Recruiting | 2026-08-11 |
| Phase 1 | ||||
| NCT05997615 | Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate… | Hormone-refractory Prostate Cancer | Recruiting | 2026-10-07 |
Gastric Cancer (8) · Pancreatic Cancer (7) · Prostate Cancer (6) · Bladder Cancer (4) · Lung Cancer (3) · Non-Small Cell Lung Cancer (NSCLC) (3) · Acute Myeloid Leukemia (AML) (1) · Cholangiocarcinoma (1) · Chronic Kidney Disease (1) · Colorectal Cancer (1)